abs161.txt	neoplastic	cellularity	contributes	to	the	analytic	sensitivity	of	most	presenttechnologies	for	mutation	detection		such	that	they	underperform	when	stroma	andinflammatory	cells	dilute	a	cancer	specimen's	variant	fraction		thus		tumorpurity	assessment	by	light	microscopy	is	used	to	determine	sample	adequacy	beforesequencing	and	to	interpret	the	significance	of	negative	results	and	mutantallele	fraction	afterwards		however		pathologist	estimates	of	tumor	purity	areimprecise	and	have	limited	reproducibility		with	the	advent	of	massively	parallelsequencing		large	amounts	of	molecular	data	can	be	analyzed	by	computationalpurity	algorithms		we	retrospectively	compared	tumor	purity	of	3	computationalalgorithms	with	neoplastic	cellularity	using	hematoxylin	and	eosin	lightmicroscopy	to	determine	which	was	best	for	clinical	evaluation	of	molecularprofiling		data	were	analyzed	from	881	cancer	patients	from	a	clinical	trialcohort		lccc1108	(uncseq)		whose	tumors	had	targeted	massively	parallelsequencing		concordance	among	algorithms	was	poor		and	the	specimens	analyzed	hadhigh	rates	of	algorithm	failure	partially	due	to	variable	tumor	purity	computational	tumor	purity	estimates	did	not	add	value	beyond	the	pathologist'sestimate	of	neoplastic	cellularity	microscopy		to	improve	present	methods		wepropose	a	semiquantitative		clinically	applicable	strategy	based	on	mutant	allelefraction	and	copy	number	changes	present	within	a	given	specimen		which	whencombined	with	the	morphologic	tumor	purity	estimate		guide	the	interpretation	ofnext-generation	sequencing	results	in	cancer	patients	this	is	an	open-accessarticle	distributed	under	the	terms	of	the	creative	commons	attribution-noncommercial-no	derivatives	license	4	0	(ccby-nc-nd)		where	it	is	permissible	todownload	and	share	the	work	provided	it	is	properly	cited		the	work	cannot	bechanged	in	any	way	or	used	commercially	without	permission	from	the	journal	http	//creativecommons	org/licenses/by-nc-nd/4	0/	
